Guidelines for Differentiating Type 1 from Type 2 Diabetes

Clinical Assessment (American Diabetes Association)

• The AABBCC clinical framework combined with autoantibody and C‑peptide testing is recommended to distinguish type 1 from type 2 diabetes. 1
• Age < 35 years strongly suggests type 1 diabetes, whereas older age favors type 2 diabetes. 1
• Misdiagnosis occurs in approximately 40 % of adults with new‑onset type 1 diabetes. 1
• A personal or family history of autoimmune disease (including polyglandular autoimmune syndromes) points toward type 1 diabetes. 1
• Body‑mass index < 25 kg/m² suggests type 1 diabetes; BMI ≥ 25 kg/m² together with absence of weight loss and ketoacidosis indicates type 2 diabetes. 1
• A family history of type 1 diabetes supports a type 1 diagnosis, while a family history of type 2 diabetes is less discriminatory. 1
• Failure to achieve glycemic targets on non‑insulin therapies suggests type 1 diabetes. 1
• Treatment with immune‑checkpoint inhibitors can precipitate acute autoimmune type 1 diabetes. 1

Typical Presentation Patterns (American Diabetes Association)

• Type 1 diabetes commonly presents acutely with marked hyperglycemia, unintentional weight loss, and ketoacidosis or ketosis. 1
• Between 25 % and 50 % of individuals with type 1 diabetes present with life‑threatening diabetic ketoacidosis. 2
• Type 2 diabetes usually shows less marked hyperglycemia, a longer and milder symptom course, and absence of ketoacidosis. 1

Autoantibody Testing (American Diabetes Association)

• Initial testing should measure glutamic acid decarboxylase (GAD) antibodies; if negative, islet tyrosine phosphatase‑2 (IA‑2) and zinc transporter‑8 (ZnT8) antibodies are added. 1
• Positive autoantibodies confirm a type 1 diabetes diagnosis regardless of clinical features. 3
• Approximately 5‑10 % of people with type 1 diabetes are antibody‑negative; a negative result in a young adult with acute onset does not exclude type 1 diabetes. 1
• In patients < 35 years without clinical features of type 2 or monogenic diabetes, a negative antibody panel does not change the diagnosis of type 1 diabetes. 1
• Using a complete four‑antibody panel (GAD, IA‑2, ZnT8, insulin‑autoantibodies) maximizes diagnostic sensitivity. 3

C‑Peptide Measurement (American Diabetes Association)

• C‑peptide testing is indicated only in insulin‑treated patients when diabetes classification is uncertain. 1
• A random C‑peptide sample obtained within 5 hours after a meal can replace formal stimulation testing. 1
• C‑peptide should not be measured within 2 weeks of a hyperglycemic emergency. 1
• Interpretation thresholds:
  
  • < 200 pmol/L (< 0.6 ng/mL) is consistent with type 1 diabetes. 1
  • < 80 pmol/L (< 0.24 ng/mL) indicates absolute insulin deficiency and does not require repeat testing. 1
  • 200‑600 pmol/L (0.6‑1.8 ng/mL) may represent type 1 diabetes, MODY, or insulin‑treated type 2 diabetes. 1
  • > 600 pmol/L (> 1.8 ng/mL) suggests type 2 diabetes. 1
• If C‑peptide is < 600 pmol/L and concurrent glucose is < 70 mg/dL, the test should be repeated. 1
• Intermediate C‑peptide values (200‑600 pmol/L) can occur in long‑standing insulin‑treated type 2 diabetes, especially in individuals with normal or low BMI. 1

Diagnostic Algorithm (American Diabetes Association)

Common Pitfalls (American Diabetes Association)

• Do not rely solely on BMI; obesity is increasingly common in type 1 diabetes, reducing its discriminatory value.
• Do not assume age > 35 years excludes type 1 diabetes—adult‑onset type 1 diabetes is frequently misdiagnosed as type 2. 1
• C‑peptide testing should not be performed in non‑insulin‑treated patients for classification purposes. 1
• A single positive autoantibody in a patient who otherwise appears to have type 2 diabetes does not definitively establish type 1 diabetes; the positive predictive value is modest in low‑probability settings.
• Recognize ketosis‑prone type 2 diabetes, which can present with ketoacidosis, particularly in individuals of African descent. 1

Guideline for Differentiating Young‑Onset Diabetes Using the AABBCC Framework, Autoantibody Testing, and C‑Peptide Measurement

Clinical Assessment – AABBCC Framework

• The American Diabetes Association recommends the AABBCC approach (Age, Autoimmunity, Body habitus, Background, Control, Comorbidities) as the first‑line clinical tool for individuals diagnosed with diabetes before age 40【4】.
• Age: Diagnosis < 35 years strongly suggests type 1 diabetes; diagnosis ≥ 35 years favors type 2 diabetes【4】.
• Autoimmunity: Personal or family history of autoimmune conditions (e.g., thyroid disease, celiac disease, polyglandular syndromes) points toward type 1 diabetes【4】.
• Body habitus: Body‑mass‑index < 25 kg/m² suggests type 1 diabetes; BMI ≥ 25 kg/m² with no weight loss or ketoacidosis indicates type 2 diabetes【4】.
• Background: Family history of type 1 diabetes supports a type 1 diagnosis; a multigenerational autosomal‑dominant pattern strongly suggests MODY【4】.
• Control: Failure to achieve glycemic targets on non‑insulin therapies suggests type 1 diabetes【4】.
• Comorbidities: Use of immune‑checkpoint inhibitors can precipitate acute autoimmune type 1 diabetes【4】.

Laboratory Testing Algorithm

Autoantibody Testing

• Order pancreatic autoantibodies (initially GAD, followed by IA‑2, ZnT8, and insulin autoantibodies if needed) in all individuals < 35 years at diagnosis, regardless of clinical presentation【4】.
• A negative autoantibody panel does not exclude type 1 diabetes; 5‑10 % of type 1 patients are antibody‑negative【4】.

C‑Peptide Measurement

• Perform random C‑peptide testing only in insulin‑treated individuals when diabetes classification remains uncertain, and avoid testing within 2 weeks of a hyperglycemic emergency【5】.
• Measure random C‑peptide within 5 hours after a meal to replace formal stimulation testing【5】.
• Interpretation thresholds:
  
  • < 80 pmol/L (≈ 0.24 ng/mL) indicates absolute insulin deficiency and confirms type 1 diabetes; repeat testing not required【5】.
  • < 200 pmol/L (≈ 0.6 ng/mL) is consistent with type 1 diabetes【5】.
  • 200‑600 pmol/L (≈ 0.6‑1.8 ng/mL) may represent type 1 diabetes, MODY, or insulin‑treated type 2 diabetes, especially in individuals with normal/low BMI or long disease duration【5】.
  • > 600 pmol/L (≈ 1.8 ng/mL) suggests type 2 diabetes【5】.

Management Recommendations

Type 1 Diabetes

• Immediate insulin therapy is mandatory for type 1 diabetes【4】【6】.
• Preferred regimens include basal‑bolus insulin or insulin‑pump therapy, continuous glucose monitoring, and diabetes self‑management education【6】.

Type 2 Diabetes

• Initiate metformin as first‑line pharmacotherapy for type 2 diabetes【6】.
• Add a GLP‑1 receptor agonist or SGLT2 inhibitor based on comorbidities (e.g., cardiovascular disease, chronic kidney disease)【6】.
• Consider insulin therapy when fasting glucose ≥ 250 mg/dL or HbA1c ≥ 8.5 %【6】.

Common Pitfalls to Avoid

• Do not rely solely on BMI; obesity is increasingly common in type 1 diabetes, reducing its discriminatory value【4】.
• Do not assume age > 35 years excludes type 1 diabetes; adult‑onset type 1 (including LADA) accounts for ~40 % of misdiagnoses when age is used as the sole criterion【4】【5】.
• Do not assume a negative autoantibody panel excludes type 1 diabetes in young individuals with acute presentation【4】.
• Do not measure C‑peptide within 2 weeks of ketoacidosis or other hyperglycemic emergencies, as results may be misleading【5】.

Guidelines for Diagnosis, Risk Assessment, and Screening of Young‑Onset Diabetes

1. Definitions and Clinical Entities

• Young‑onset diabetes is defined as diabetes diagnosed before age 40 and includes type 1 diabetes, type 2 diabetes, maturity‑onset diabetes of the young (MODY), and neonatal diabetes. 7
• Neonatal diabetes (onset < 6 months) is monogenic in ≈ 80‑85 % of cases. 7
• All individuals diagnosed with diabetes in the first 6 months of life should undergo immediate genetic testing for monogenic causes, irrespective of current age. 7
• Type 1 diabetes is exceedingly rare before 6 months; therefore, monogenic etiologies are the primary consideration in this age group. 7
• The earliest documented case of type 2 diabetes in a child occurred in a 4‑year‑old individual. 8

2. Neonatal Diabetes

• Neonatal diabetes can be transient (often due to chromosome 6q24 over‑expression) or permanent; the transient form is the most common genetic mechanism. 9

3. Maturity‑Onset Diabetes of the Young (MODY)

• MODY typically presents with hyperglycemia before age 25, although diagnosis may be made later. 7
• It is characterized by impaired insulin secretion with minimal insulin resistance (in the absence of obesity) and follows an autosomal‑dominant inheritance pattern. 7
• At least 13 causative genes have been identified; the most frequent are GCK (MODY2), HNF1A (MODY3), and HNF4A (MODY1). 7
• Genetic testing for MODY is recommended in children and young adults who lack classic type 1 or type 2 features and have a multigenerational family history of diabetes. 7

4. Type 2 Diabetes in Children and Adolescents

• The peak age of diagnosis for pediatric type 2 diabetes is during puberty (approximately 12‑16 years), though cases have been reported in pre‑pubertal children. 8
• Screening for type 2 diabetes should begin at the onset of puberty or at age 10 years (whichever is earlier) in overweight (BMI ≥ 85th percentile) or obese (BMI ≥ 95th percentile) children who have additional risk factors. 10
• The rise of pediatric type 2 diabetes is strongly linked to the obesity epidemic and reduced physical activity levels. 8
• Approximately 85 % of affected children are obese, with mean BMI values ranging from 27 to 38 kg/m². 8

5. Key Risk Factors for Young‑Onset Type 2 Diabetes

5.1 Strongest Risk Factors (Evidence Grade A)

• Maternal diabetes or gestational diabetes during pregnancy. 11
• Family history of type 2 diabetes in first‑ or second‑degree relatives (reported in 74‑100 % of pediatric cases). 8
• High‑risk racial/ethnic groups: Native American, African American, Latino, Asian American, and Pacific Islander. 11

5.2 Additional Risk Factors (Evidence Grade B)

• Clinical signs of insulin resistance (e.g., acanthosis nigricans, hypertension, dyslipidemia, polycystic ovary syndrome). 11
• Small‑for‑gestational‑age birth weight. 11
• Female sex, which shows a higher frequency in most pediatric studies. 8

6. Diagnostic Pitfalls and Misclassification

• Age > 35 years does not reliably exclude type 1 diabetes; misdiagnosis occurs in roughly 40 % of adults with new‑onset type 1 diabetes. 12
• Distinguishing type 1 from type 2 diabetes in children is challenging because obesity is common in type 1 diabetes and autoantibodies or ketosis may be present in pediatric type 2 diabetes. 10